<DOC>
	<DOCNO>NCT01998880</DOCNO>
	<brief_summary>This open-label , randomize , 3-arm study evaluate efficacy safety obinutuzumab ( RO5072759 ) combination chlorambucil compare rituximab plus chlorambucil chlorambucil alone patient previously untreated chronic lymphocytic leukemia ( CLL ) . Patients randomize 2:2:1 receive maximum six 28-day cycle either RO5072759 ( 1000mg iv infusion , day 1 , 8 15 cycle 1 day 1 cycle 2-6 ) plus chlorambucil ( 0.5 mg/kg orally , day 1 15 cycle 1-6 ) , rituximab ( iv infusion day 1 , 375 mg/m^2 cycle 1 , 500 mg/m^2 cycle 2-6 ) plus chlorambucil , chlorambucil alone . Anticipated time study treatment &gt; 6 month follow-up disease-progression safety least 5 year . In US , trial sponsored/managed Genentech .</brief_summary>
	<brief_title>CLL11 : A Study Rituximab With Chlorambucil Chlorambucil Alone Patients With Previously Untreated Chronic Lymphocytic Leukemia ( Stage 1b )</brief_title>
	<detailed_description>Protocol BO21004 divide 3 separate Unique Protocol IDs report result clinicaltrials.gov 3 separate primary analysis conduct different time-points . - BO21004 ( Stage 1a ) [ NCT01010061 ] include analysis 2 3 arm obinutuzumab plus chlorambucil ( Glb ) compare chlorambucil ( Clb ) report separately . - BO21004 ( Stage 1b ) [ NCT01998880 ] include analysis 2 3 arm rituximab plus chlorambucil ( RClb ) compare chlorambucil ( Clb ) report . - BO21004 ( Stage 2 ) [ NCT02053610 ] include analysis 2 3 arm obinutuzumab plus chlorambucil ( Glb ) compare rituximab plus chlorambucil ( RClb ) report separately .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>Adults &gt; /=18 year Documented Cluster Differentiation Antigen 20 ( CD20 ) + BCell Chronic Lymphocytic Lymphoma ( BCLL ) Previously untreated Chronic Lymphocytic Leukemia ( CLL ) require treatment accord National Cancer Institute ( NCI ) criteria Total Cumulative Illness Rating Scale ( CIRS ) &gt; 6 and/or creatinine clearance &lt; 70 ml/min Prior CLL therapy Transformation CLL aggressive NonHodgkin 's Lymphoma ( NHL ) ( Richter 's transformation ) History malignancy unless malignancy remission without treatment &gt; /=2 year prior enrolment , except carcinoma situ cervix , basal squamous cell skin cancer , surgically treat lowgrade prostate cancer , ductal carcinoma situ ( DCIS ) breast treated lymphectomy alone Positive hepatitis serology ( HBV , HCV ) positive HIV Human T Cell Leukemia Virus ( HTLV ) test Patients active infection require systemic treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>